According to an announcement from GENSCRIPT BIO (ASX: 01548), the net trade sales for CARVYKTI® in the quarter ended June 30, 2026, amounted to approximately $657 million.
This figure is reported under the terms of the collaboration and license agreement established between Legend and Janssen Biotech, Inc. on December 21, 2017.